August 2019

ChemomAb Ltd., Announces Data from Phase 1 Study of CM-101 Subcutaneous Formulation Demonstrating Comparable Exposure to The Intravenous CM-101 Formulation

https://www.businesswire.com/news/home/20190821005230/en/ChemomAb-Ltd.-Announces-Data-Phase-1-Study

May 2019

ChemomAb announces a peer reviewed publication of pre clinical proof of concept data supporting the pivotal role of CCL24 in systemic sclerosis and idiopathic pulmonary fibrosis. The paper “Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis” was published in May 2019 edition of “Annals of Rheumatoid Diseases” and  supports the therapeutic potential of CM-101 for the treatment of patients with Systemic Sclerosis.

Annals of Rheumatoid Diseases is a top line peer reviewed journal which publishes basic, clinical and translational novel scientific research, owned by the European League Against Rheumatism (EULAR) and BMJ.

Blockade of CCL24 with a monoclonal antibody

April 2019

ChemomAb doses first subject in a phase 1 clinical trial of Subcutaneous injected CM-101 in healthy volunteers

April 2019

ChemomAb to present “Attenuation of CCL24, using CM-101- a Novel monoclonal antibody, reduces cholangiocytes proliferation in experimental cholestasis models” at EASL International Liver Congress 2019.

ILC_2019_ final

 

ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 in Patients With Non-Alcoholic Fatty Liver Disease

https://www.businesswire.com/news/home/20190110005140/en/ChemomAb-Doses-Patient-Phase-1b-Clinical-trial

December 2018

ChemomAb appoints Bryan Jennings as Chief Financial Officer

November  2018

ChemomAb to Present “CM101, A novel CCL24 blocking antibody, suppresses hepatic injury and fibrosis in  experimental models of NASH and liver fibrosis” at AASLD international Liver meeting in San Francisco 2018

October 2018

ChemomAb was granted an Orphan Drug Designation from the FDA for the treatment of Primary Sclerosis Cholangitis

October 2018

ChemomAb appoints Dr. Stephen Squinto as Chairman of the Board:

https://www.businesswire.com/news/home/20181204005275/en/ChemomAb-Appoints-Dr.-Stephen-Squinto-Chairman-Board

April 2018

ChemomAb presents “A novel CCL24 blocking monoclonal antibody ameliorates liver injury in experimental models of cholestasis” at EASL International Liver Congress 2018.

March 2018

ChemomAb successfully completed Phase 1 in healthy volunteers, achieving its primary endpoint of safety, pharmacokinetics and pharmacodynamics.

November 2017

ChemomAb completed a $10 million series B fund raising supported by Orbimed Israel, Peter Thiel, SBI Japan-Israel innovation Fund and Milestone venture.

October 2017

ChemomAb to present ” CM-101, a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse model” at AASLD’s Liver Meeting® 2017.

September 2017

ChemomAb received OCS grant for the development of the CM101 program.

July 2017

ChemomAb initiated its first in man clinical trial to test the safety, pharmacokinetic and pharmacodynamic profile of its lead drug CM101 in healthy volunteers.

June 2017

ChemomAb presents “Circulating levels of the chemokine CCL24 and its receptor in patients with non-alcoholic fatty liver disease” in the Israeli Liver convention.

November 2016

ChemomAb assembles advisory board meeting with Scleroderma key opinion leaders to discuss the outline of its clinical trial in Washington.

June 2016

ChemomAb receives formal scientific advice from EMA for pre-clinical and clinical development of its lead first in class monoclonal antibody CM101.

Febuary 2016

ChemomAb orally presented “CM-101, A NOVEL MONOCLONAL ANTIBODY BLOCKING CCL24 AMELIORATES EXPERIMENTAL SYSTEMIC SCLEROSIS (SSC) AND IDIOPATHIC PULMONARY FIBROSIS (IPF) and A NOVEL ANTIBODY BLOCKING CCL24/CCR3 REDUCESCHEMOKINESIS OF IMMUNE CELLS AND THE TRANSITION OF FIBROBLASTS TO MYOFIBROBLASTS IN SYSTEMIC SCLEROSIS (SSC)” in the Systemic Sclerosis World Congress.

For further information published by Scleroderma News click here

December 2015

ChemomAb is granted approval for its patent: ” Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders ” in USA, Europe and Israel.

December 2015

ChemomAb has engaged CMC Biologics for a full manufacturing program to generate GMP material for clinical trials.

October 2015

ChemomAb received a second FDA approved orphan drug designation, for idiopathic pulmonary fibrosis treatment with CM101.

January 2015 

ChemomAb was granted orphan drug designation by the FDA, to treat systemic sclerosis patients with CM101.

October 2014

ChemomAb received an orphan drug designation approval from the EMA for CM101 treatment in systemic sclerosis.